11,436 reports of this reaction
7.8% of all PEGFILGRASTIM reports
#1 most reported adverse reaction
DEVICE ADHESION ISSUE is the #1 most commonly reported adverse reaction for PEGFILGRASTIM, manufactured by Amgen, Inc. There are 11,436 FDA adverse event reports linking PEGFILGRASTIM to DEVICE ADHESION ISSUE. This represents approximately 7.8% of all 146,341 adverse event reports for this drug.
Patients taking PEGFILGRASTIM who experience device adhesion issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVICE ADHESION ISSUE is moderately reported among PEGFILGRASTIM users, representing a notable but not dominant share of adverse events.
In addition to device adhesion issue, the following adverse reactions have been reported for PEGFILGRASTIM:
The following drugs have also been linked to device adhesion issue in FDA adverse event reports:
DEVICE ADHESION ISSUE has been reported as an adverse event in 11,436 FDA reports for PEGFILGRASTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVICE ADHESION ISSUE accounts for approximately 7.8% of all adverse event reports for PEGFILGRASTIM, making it one of the most commonly reported side effect.
If you experience device adhesion issue while taking PEGFILGRASTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.